

1 **Title:** County by county estimation of deaths averted, infections averted, and cost
2 savings of overdose prevention health centers in the United States

3 **Authors:** Mike Sportiello, PhD¹, Rohith Palli MD/PhD²

4 1. Medical Scientist Training Program at the University of Rochester Medical
5 Center. 601 Elmwood Avenue Rochester, NY 14642.

6 2. Internal Medicine Residency at the University of Rochester Medical Center. 601
7 Elmwood Avenue Rochester, NY 14642.

8 **Abstract**

9 Overdose prevention health centers (OPHCs), also known as overdose
10 prevention centers or safe injection centers, are an evidence-based strategy for people
11 to use drugs in an environment monitored by health care professionals with access to
12 drug use education, sterile supplies, and referral infrastructure to access higher levels of
13 medical and behavioral health resources. Though still illegal under federal law
14 throughout the United States, many legal or quasi-legal (including some in the United
15 States) have operated since the 1980s (Beletsky, Baker et al. 2018). Using CDC
16 overdose deaths and United States Census Bureau population data, we estimate over
17 14,000 deaths could be averted between 2020 and 2022 if 1 out of 20 injections had
18 taken place at an OPHC. At this rate, over 100 HIV transmissions and 57,000 Hepatitis
19 C Virus transmissions would have been averted as well. Almost 20 billion dollars in
20 discounted lifetime costs to treat those infections could have been saved as well. This
21 data supports OPHCs as a viable public health intervention to avert deaths and avoid
22 infections.

23

1

24 **Introduction**

25 Overdose prevention health centers (OPHCs), also known as overdose
26 prevention centers or safe injection centers, are an evidence-based strategy for people
27 to use drugs in an environment monitored by health care professionals with access to
28 drug use education, sterile supplies, and referral infrastructure to access higher levels of
29 medical and behavioral health resources. Though still illegal under federal law
30 throughout the United States, many legal or quasi-legal (including some in the United
31 States) have operated since the 1980s (Beletsky, Baker et al. 2018). Since this time,
32 there have been reported overdoses, but no reported deaths in this supervised health
33 care setting, as naloxone, an opioid overdose reversal agent as well as access to
34 respiratory therapy like supplemental oxygen or ventilation is readily available. Other
35 studies have focused on assessing the impact of an OPHC in their community (Irwin,
36 Jozaghi et al. 2016), but no study has analyzed all United States counties and modeled
37 the likely impact. In this analysis, we analyze how many deaths averted, infections
38 averted, and the cost savings accrued had the county adopted OPHCs during this time.

39 **Methods**

40 Drug overdose deaths by month per county were accessed from the National
41 Center for Health Statistics from 2020-2022. Population and age data were downloaded
42 from the United States Census Bureau. County names were standardized. For this
43 analysis, we estimated 1.5% of adults were people who injected drugs (PWID) per
44 others' work (Bradley, Hall et al. 2023). For each PWID, we estimated 508.8 injections
45 per year, or just under 1.5 injections per day per other's work (Bradley, Hall et al. 2023).

46 Deaths averted

47 Deaths averted was calculated by assuming the total number of injections stayed
48 constant. Secondly, we assumed that deaths cannot occur after an injection in the
49 OPHC, as no overdose death has ever occurred in an OPHC. The *injections that would*
50 *occur at OPHC* was calculated by modeling 2.5%, 5%, 7.5%, or 10% of injections taking
51 place at the OPHC. This led to the following calculation:

$$\frac{\text{Injections that would occur at OPHC}}{\text{PWID} * \text{Injections per person}} * \text{Overdose deaths} = \text{Deaths averted}$$

52 With the fraction on the left simplifying to the frequency of total injections in the OPHC,
53 multiplied by the number of deaths. If all the injections took place at the OPHC, the
54 leftmost fraction would simplify to 1 and all deaths would be averted. If none did, the
55 whole left term would simplify to 0 and no deaths would be averted.

56 HCV transmissions averted

57 Hepatitis C virus (HCV) is a highly transmissible virus in the setting of shared
58 needle use, leading to significant morbidity, mortality, and health expenditures. While
59 curative therapy now exists, it is expensive and requires weeks-long adherence which is
60 difficult for many who inject drugs as they are disproportionately housing insecure.
61 Similar to deaths averted, due to the supply of sterile drug use equipment including
62 needles and cottons, transmission of HCV has never been documented at an OPHC.
63 Natural incidence of HCV within PWID varies widely, with studies with varying from 0.51
64 to 47 per 100 person years. For this analysis, we used a lower-end estimate of 10 per
65 100 person years (Gutfraind, Boodram et al. 2015), leading to the following equation:

$$\frac{\text{Injections that would occur at OPHC}}{\text{PWID} * \text{Injections per person}} * \text{HCV incidence} = \text{HCV transmissions averted}$$

66 HIV transmissions averted

67 Though the vast majority of HIV is not transmitted through injection drug use, it is
68 still a meaningful target of HIV transmission prevention efforts. Others have calculated
69 the incidence of HIV transmission in groups of people who inject drugs, stratifying their
70 use as low, medium, and high risk depending on factors including how often they share
71 needles with people they know and alternatively with strangers (Jarlais, Bobashev et al.
72 2022). Using these incidences, we calculated HIV transmissions averted with the
73 following equations:

$$\frac{\text{Injections that would occur at OPHC}}{\text{PWID} * \text{Injections per person}} * \text{HIV incidence low risk}$$
$$= \text{HIV transmissions averted}$$

$$\frac{\text{Injections that would occur at OPHC}}{\text{PWID} * \text{Injections per person}} * \text{HIV incidence medium risk}$$
$$= \text{HIV transmissions averted}$$

$$\frac{\text{Injections that would occur at OPHC}}{\text{PWID} * \text{Injections per person}} * \text{HIV incidence high risk}$$
$$= \text{HIV transmissions averted}$$

74 Financial impact

75 Substantial health care dollars are spent treating preventable diseases.
76 Infectious diseases are a particularly good target given how easily they can be
77 prevented with appropriate education and low-cost materials. Others have estimated the
78 discounted lifetime cost of an HIV infection to be \$326,500 (Schackman, Fleishman et
79 al. 2015). We calculated the discounted lifetime cost of an HIV infection with the
80 following equation:

$\$326,500 * \textit{averted HIV transmission} = \textit{Discounted cost of an averted HIV infection}$

81 Similar work has been done to calculate the discounted lifetime cost of HCV,
82 calculated to \$320,328 (Liu, Barnett et al. 2016).

$\$320,328 * \textit{averted HCV transmission} = \textit{Discounted cost of an averted HCV infection}$

83 Finally, we calculated the total statistical costs of the lives to those who died from
84 overdose, using the dollar amount the Federal Emergency Medical Agency \$7,500,000
85 uses for their calculations, giving the following equation:

$\$7,500,000 * \textit{Averted deaths} = \textit{Statistical costs of deaths averted}$

86 Results

87 Deaths averted depends on what percentage of injections occur at the OPHC
88 (Table 1). At the low end assuming 2.5% of injections occurred at OPHCs (1 injection
89 out of 50, or one injection every 36 days $[50/(508.8/365)]$), over 7,000 deaths would
90 have been averted. At the higher end, almost 29,000 deaths could have been averted.

91 **Figure 1** maps the cumulative deaths averted assuming 5% of injections occurred at an
92 OPHC.

93

94 *Table 1: Summary table of results*

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	7212.43	14424.85	21637.28	28849.70
HCV averted	28677.43	57354.86	86032.29	114709.72
HIV-low averted	57.35	114.71	172.06	229.42
HIV-medium averted	131.92	263.83	395.75	527.66
HIV-high averted	160.59	321.19	481.78	642.37
Discounted lifetime cost of infections	9.23E+09	1.85E+10	2.77E+10	3.69E+10
Cost of life	5.41E+10	1.08E+11	1.62E+11	2.16E+11
Total costs	6.33E+10	1.27E+11	1.90E+11	2.53E+11
Total costs (billions)	63.32	126.64	189.97	253.29

95

96 HCV infections averted range from just under 29,000 to just under 115,000 (**Figure 2**).

97 Hundreds of HIV transmissions could have been averted (**Figure 3**). At least billions of

98 dollars would have been saved, if not more with higher use, from relatively low rates of

99 usage of OPHCs.

100 Even if OPHCs were only instituted in the top 50 most populous counties (Table

101 2) or the top 50 deaths per capita (Table 3), a substantial impact would be seen.

102 *Table 2: Results for 50 most populous counties*

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	2140.40	4280.80	6421.20	8561.60
HCV averted	8699.02	17398.04	26097.06	34796.08
HIV-low averted	17.40	34.80	52.19	69.59
HIV-medium averted	40.02	80.03	120.05	160.06
HIV-high averted	48.71	97.43	146.14	194.86
Discounted lifetime cost of infections	2.80E+09	5.60E+09	8.40E+09	1.12E+10
Cost of life	1.61E+10	3.21E+10	4.82E+10	6.42E+10
Total costs	1.89E+10	3.77E+10	5.66E+10	7.54E+10
Total costs (billions)	18.85	37.71	56.56	75.41

103

104 *Table 3: Results for 50 counties with most deaths per capita*

Percent injections at OPHC	2.5%	5%	7.5%	10%
Deaths averted	296.45	592.90	889.35	1185.80
HCV averted	350.41	700.83	1051.24	1401.66
HIV-low averted	0.70	1.40	2.10	2.80
HIV-medium averted	1.61	3.22	4.84	6.45
HIV-high averted	1.96	3.92	5.89	7.85
Discounted lifetime cost of infections	1.13E+08	2.26E+08	3.38E+08	4.51E+08
Cost of life	2.22E+09	4.45E+09	6.67E+09	8.89E+09
Total costs	2.34E+09	4.67E+09	7.01E+09	9.34E+09
Total costs (billions)	2.34	4.67	7.01	9.34

105

106 **Discussion**

107 While it is difficult to estimate the rates of use of OPHCs by those injecting, this
108 study supplies a framework to assist in estimating the impact on deaths, infections, and
109 cost savings. Even at very low rates of use, assuming one out of every 20 injections
110 occurs at OPHCs, tens of thousands of deaths and HCV transmissions are averted.

111 Over 100 HIV transmissions are averted. This study also analyzes the impact on if the
112 50 most populous (Table 2) or the 50 counties with the most deaths (Table 3) were to
113 construct an OPHC, a potentially more realistic and cost-effective strategy.

114 Importantly, this analysis does not include secondary benefits of OPHCs like the
115 association of people voluntarily joining detoxification programs, methadone initiation

116 programs, or long-term addiction treatment initiation (Wood, Tyndall et al. 2007). It also
117 doesn't include benefits that education has such as decreasing the rates of needle
118 sharing (Kerr, Tyndall et al. 2005). Lastly, this analysis doesn't include the benefits of
119 secondary social supports unrelated to drug use, including housing support, food
120 support, or other programs.

121 This analysis doesn't include any secondary detriments of OPHCs, though it
122 should be noted that most of those of concern (increase in overdoses, increase in new-
123 onset illicit injection drug use) have not been borne out by studies that that have actually
124 measured these important issues of concern. One important aspect not included in this
125 analysis is the cost to build and maintain these OPHCs, which would require both direct
126 costs of salaries of health and social workers, as well as maintaining these buildings
127 over time.

128 Overall, these data support the broad construction and initiation of OPHCs as a
129 measure to prevent the mortality and morbidity associated with injection drug use.

130

131 **References**

- 132 Beletsky, L., P. Baker, J. Arredondo, A. Emuka, D. Goodman-Meza, M. E. Medina-Mora, D. Werb,
133 P. Davidson, J. J. Amon, S. Strathdee and C. Magis-Rodriguez (2018). "The global health and
134 equity imperative for safe consumption facilities." *Lancet* **392**(10147): 553-554.
- 135 Bradley, H., E. W. Hall, A. Asher, N. W. Furukawa, C. M. Jones, J. Shealey, K. Buchacz, S.
136 Handanagic, N. Crepaz and E. S. Rosenberg (2023). "Estimated Number of People Who Inject
137 Drugs in the United States." *Clin Infect Dis* **76**(1): 96-102.
- 138 Gutfraind, A., B. Boodram, N. Prachand, A. Hailegiorgis, H. Dahari and M. E. Major (2015).
139 "Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in
140 Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections." *PLoS One* **10**(9):
141 e0137993.
- 142 Irwin, A., A. Jozaghi, R. N. Bluthenthal and A. H. Kral (2016). "A Cost-Benefit Analysis of a
143 Potential Supervised Injection Facility in San Francisco, California, USA." *Journal of Drug Issues*
144 **47**(2).
- 145 Jarlais, D. D., G. Bobashev, J. Feelemyer and C. McKnight (2022). "Modeling HIV transmission
146 among persons who inject drugs (PWID) at the "End of the HIV Epidemic" and during the
147 COVID-19 pandemic." *Drug Alcohol Depend* **238**: 109573.
- 148 Kerr, T., M. Tyndall, K. Li, J. Montaner and E. Wood (2005). "Safer injection facility use and
149 syringe sharing in injection drug users." *Lancet* **366**(9482): 316-318.
- 150 Liu, S., P. G. Barnett, M. Holodniy, J. Lo, V. R. Joyce, R. Gidwani, S. M. Asch, D. K. Owens and J. D.
151 Goldhaber-Fiebert (2016). "Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus
152 Infection in non-VA and VA Populations." *MDM Policy Pract* **1**(1).
- 153 Schackman, B. R., J. A. Fleishman, A. E. Su, B. K. Berkowitz, R. D. Moore, R. P. Walensky, J. E.
154 Becker, C. Voss, A. D. Paltiel, M. C. Weinstein, K. A. Freedberg, K. A. Gebo and E. Losina (2015).
155 "The lifetime medical cost savings from preventing HIV in the United States." *Med Care* **53**(4):
156 293-301.
- 157 Wood, E., M. W. Tyndall, R. Zhang, J. S. Montaner and T. Kerr (2007). "Rate of detoxification
158 service use and its impact among a cohort of supervised injecting facility users." *Addiction*
159 **102**(6): 916-919.
160

Cumulative lives saved




Figure 1: Per county cumulative lives saved assuming 1/20 injections occurred at an OPHC.

Cumulative HCV averted






Figure 2: Figure 1: Per county cumulative HCV transmissions averted assuming 1/20 injections occurred at an OPHC.

Cumulative HIV averted low



Cumulative HIV averted med



Cumulative HIV averted high





Figure 3: Figure 1: Per county cumulative HIV transmissions averted assuming 1/20 injections occurred at an OPHC according to 3 transmission dynamics: low, medium, or high.